Promising Developments in Rocket Pharmaceuticals’ KRESLADI Gene Therapy Boost Buy Rating

Rocket Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on the stock and has a $9.00 price target.

Cory Jubinville, PhD’s rating is based on several promising developments surrounding Rocket Pharmaceuticals’ KRESLADI, a gene therapy for leukocyte adhesion deficiency type I (LAD-I). The FDA has accepted the resubmission of the Biologics License Application (BLA) for KRESLADI, with a new Prescription Drug User Fee Act (PDUFA) date set for March 28, 2026. This acceptance follows a previous Complete Response Letter (CRL) due to additional CMC information requests, but the resubmission now appears to have a strong likelihood of approval given the therapy’s demonstrated 100% overall survival rate at 12 months post-infusion and its ability to provide durable benefits in follow-up studies.
Furthermore, KRESLADI addresses a significant unmet medical need, as the current standard of care, allogeneic hematopoietic stem-cell transplantation, faces challenges such as donor availability and risks like graft-versus-host disease. KRESLADI’s use of autologous CD34+ hematopoietic stem cells with a functional ITGB2 gene offers a promising alternative, restoring normal immune function in patients. Additionally, the timing of this update is advantageous, as Rocket holds several designations, including Rare Pediatric Disease (RPD), which could lead to a Priority Review Voucher (PRV) if approved, providing potential non-dilutive capital access. These factors collectively support the Buy rating for Rocket Pharmaceuticals’ stock.

In another report released today, Wedbush also maintained a Buy rating on the stock with a $16.00 price target.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is neutral on the stock.